Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

­Vuzix Schedules Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update

share with twitter share with LinkedIn share with facebook
08/05/2019 | 09:01am EDT

ROCHESTER, N.Y., Aug. 5, 2019 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, is pleased to announce that the Company has scheduled a conference call on Friday, August 9, 2019, at 8:30 AM Eastern Time (ET) to review its operating results for the quarter ended June 30, 2019.

Date: Friday, August 9, 2019
Time: 8:30 AM Eastern Time (ET)
Dial-in Number for U.S. and Canadian Callers: 877-709-8150 
Dial-in Number for International Callers (Outside of the U.S. and Canada): 201-689-8354

(PRNewsfoto/Vuzix Corporation)

Participating on the call will be Vuzix Chief Executive Officer and President Paul Travers and Chief Financial Officer Grant Russell, who will discuss operational and financial highlights for the quarter ended June 30, 2019.

To join the live conference call, please dial the above referenced telephone numbers 10 to 15 minutes prior to the scheduled call time. Participants can also click this link for instant telephone access to the event. The link will become active approximately 15 minutes prior to the start of the conference call.

Investors who would like to submit questions to management for response during the call's Q&A session, time permitting, can do so by emailing Ed McGregor at ed_mcgregor@vuzix.com prior to the start of the call.

A replay will be available for 30 days starting on August 9, 2019, at approximately 10:30 AM (ET). To access the replay, please dial 877-660-6853 in the U.S. or Canada and 201-612-7415 for international callers. The conference ID# is 13693456.

About Vuzix Corporation

Vuzix is a leading supplier of Smart-Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The Company's products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and augmented reality. Vuzix holds 146 patents and patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2019 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (VUZI) with offices in Rochester, NY, Oxford, UK, and Tokyo, Japan.  For more information, visit Vuzix websiteTwitter and Facebook pages.

Media and Investor Relations Contact:

Ed McGregor, Director of Investor Relations, Vuzix Corporation ed_mcgregor@vuzix.com  
Tel: (585) 359-5985

Vuzix Corporation, 25 Hendrix Road, Suite A, West Henrietta, NY 14586 USA,
Investor Information – IR@vuzix.com www.vuzix.com

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/vuzix-schedules-conference-call-to-discuss-second-quarter-2019-financial-results-and-business-update-300896114.html

SOURCE Vuzix Corporation

© PRNewswire 2019

share with twitter share with LinkedIn share with facebook
Latest news "Companies"
11:14aEXCLUSIVE : Ant Group's Shanghai IPO gets bids in 68-69 yuan/share range, say sources
RE
11:07aORGANOCLICK : winner of Clean Equity Monaco Award given out by H.S.E Prince Albert II of Monaco
AQ
10:55aVEDANTA : Intimation for declaration of first Interim Dividend for FY 2020-21
PU
10:53aCOCA-COLA EUROPEAN PARTNERS IN TALKS TO BUY COCA-COLA AMATIL : Bloomberg
RE
10:40aREVOLUTION MEDICINES : Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
PU
10:16aTURNING POINT THERAPEUTICS : Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
AQ
10:16aTurning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
GL
10:00aFINAL DEADLINE ALERT : ROSEN, A LEADING AND RANKED FIRM, Reminds Progenity, Inc. Investors of Important October 27 Deadline in Securities Class Action – PROG
GL
09:46a(GOCO) ALERT : GoHealth Investors Reminded of Class Action Deadline; Investors with Losses Over $100,000 Encouraged to Contact Firm - Johnson Fistel, LLP
PR
09:46aREVOLUTION MEDICINES : Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
AQ
Latest news "Companies"